Grandi, Guido
 Distribuzione geografica
Continente #
NA - Nord America 6.637
AS - Asia 2.712
EU - Europa 1.537
SA - Sud America 675
AF - Africa 67
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 11.641
Nazione #
US - Stati Uniti d'America 6.552
SG - Singapore 959
VN - Vietnam 690
CN - Cina 565
BR - Brasile 541
IT - Italia 297
RU - Federazione Russa 287
SE - Svezia 161
FI - Finlandia 159
GB - Regno Unito 120
FR - Francia 108
LV - Lettonia 91
DE - Germania 89
HK - Hong Kong 87
KR - Corea 74
TR - Turchia 62
BG - Bulgaria 60
ID - Indonesia 59
AR - Argentina 54
IN - India 54
BD - Bangladesh 49
CA - Canada 34
MX - Messico 30
EC - Ecuador 29
UA - Ucraina 29
IQ - Iraq 24
ZA - Sudafrica 24
NL - Olanda 22
PL - Polonia 22
AT - Austria 18
CO - Colombia 17
ES - Italia 17
CL - Cile 13
JP - Giappone 12
AU - Australia 10
CZ - Repubblica Ceca 10
PK - Pakistan 10
DZ - Algeria 8
MA - Marocco 8
SK - Slovacchia (Repubblica Slovacca) 8
TN - Tunisia 8
AE - Emirati Arabi Uniti 7
CH - Svizzera 7
PE - Perù 7
TH - Thailandia 7
UZ - Uzbekistan 7
PH - Filippine 6
PY - Paraguay 6
VE - Venezuela 6
EG - Egitto 5
IE - Irlanda 5
KE - Kenya 5
KZ - Kazakistan 5
PT - Portogallo 5
RO - Romania 5
BE - Belgio 4
IL - Israele 4
JO - Giordania 4
LT - Lituania 4
TW - Taiwan 4
AM - Armenia 3
ET - Etiopia 3
NP - Nepal 3
PR - Porto Rico 3
SA - Arabia Saudita 3
BB - Barbados 2
BW - Botswana 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GR - Grecia 2
GT - Guatemala 2
IR - Iran 2
JM - Giamaica 2
KG - Kirghizistan 2
NI - Nicaragua 2
PA - Panama 2
RS - Serbia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
AZ - Azerbaigian 1
BH - Bahrain 1
BO - Bolivia 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
EU - Europa 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
KH - Cambogia 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
MQ - Martinica 1
MU - Mauritius 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
OM - Oman 1
Totale 11.637
Città #
Fairfield 852
Ashburn 611
Singapore 594
Chandler 494
Woodbridge 390
Seattle 373
Houston 321
Wilmington 315
Cambridge 309
San Jose 221
Santa Clara 210
Ho Chi Minh City 189
Ann Arbor 178
Dallas 178
Columbus 167
Princeton 164
Jacksonville 151
San Mateo 151
Beijing 149
Hanoi 133
Moscow 125
Riga 91
Dong Ket 90
Helsinki 85
Hong Kong 83
The Dalles 83
Council Bluffs 82
Lauterbourg 80
Los Angeles 73
Seoul 73
Hangzhou 69
New York 63
Sofia 57
San Diego 55
Trento 54
Dearborn 53
Izmir 51
São Paulo 45
Da Nang 40
Jakarta 39
Phoenix 35
San Paolo di Civitate 33
Buffalo 30
Chicago 30
Orem 30
London 25
Como 24
Haiphong 24
Munich 24
Boardman 21
Rio de Janeiro 20
Warsaw 18
Chennai 16
Norwalk 16
Rome 16
Altamura 15
Johannesburg 15
Guangzhou 14
Hefei 14
Atlanta 13
Biên Hòa 13
Hải Dương 12
Nuremberg 12
Montreal 11
Thái Bình 11
Toronto 11
Baghdad 10
Brooklyn 10
Can Tho 10
Redondo Beach 10
Salt Lake City 10
Tokyo 10
Brasília 9
Des Moines 9
Frankfurt am Main 9
Nanjing 9
Ninh Bình 9
Quito 9
Stockholm 9
Belo Horizonte 8
Bratislava 8
Brno 8
Bắc Ninh 8
Fortaleza 8
Fremont 8
Manchester 8
Naples 8
Schio 8
Shanghai 8
Tavagnacco 8
Turku 8
Amsterdam 7
Boston 7
Campinas 7
Denver 7
Düsseldorf 7
Guarulhos 7
Mexico City 7
Miano 7
Milan 7
Totale 8.326
Nome #
Prochymosin expression in Bacillus subtilis 247
Protectome analysis: A new selective bioinformatics tool for bacterial vaccine candidate discovery 237
Some Gram-negative lipoproteins keep their surface topology when transplanted from one species to another and deliver foreign polypeptides to the bacterial surface 231
Vaccination with a FAT1-derived B cell epitope combined with tumor-specific B and T cell epitopes elicits additive protection in cancer mouse models 231
Structure of the type IX Group B Streptococcus capsular polysaccharide and its evolutionary relationship with types V and VII 221
Auto-assembling detoxified staphylococcus aureus alpha-hemolysin mimicking the wild-type cytolytic toxin 218
Vaccine composition formulated with a novel TLR7-dependent adjuvant induces high and broad protection against Staphylococcus aureus 216
Analysis of two-component systems in group B streptococcus shows that RgfAC and the novel FspSR modulate virulence and bacterial fitness 198
Streptococcus agalactiae capsule polymer length and attachment is determined by the proteins CpsABCD 196
One dose of staphylococcus aureus 4C-staph vaccine formulated with a novel TLR7-dependent adjuvant rapidly protects mice through antibodies, effector CD4+ T Cells, and IL-17A 196
Synergistic protective activity of tumor-specific epitopes engineered in bacterial outer membrane vesicles 194
The human pathogen Streptococcus pyogenes releases lipoproteins as lipoprotein-rich membrane vesicles 194
Bacterial outer membrane vesicles engineered with lipidated antigens as a platform for Staphylococcus aureus vaccine 192
Whole-genome epidemiology, characterisation, and phylogenetic reconstruction of Staphylococcus aureus strains in a paediatric hospital 186
CD81 extracellular domain 3D structure: Insight into the tetraspanin superfamily structural motifs 185
Vaccinology: The art of putting together the right ingredients 180
Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting 180
Protective effect of Group B Streptococcus type-III polysaccharide conjugates against maternal colonization, ascending infection and neonatal transmission in rodent models 176
Large scale validation of an efficient CRISPR/Cas-based multi gene editing protocol in Escherichia coli 175
Understanding the Molecular Determinants Driving the Immunological Specificity of the Protective Pilus 2a Backbone Protein of Group B Streptococcus 171
Angiopoietin-like 7, a novel pro-angiogenetic factor over-expressed in cancer 167
Proteome-minimized outer membrane vesicles from Escherichia coli as a generalized vaccine platform 166
Genomic analysis reveals the molecular basis for capsule loss in the group B Streptococcus population 164
Identification of the central tolerance checkpoint for autoreactive proteinase 3+ B cells in human bone marrow 163
Targeted amino acid substitutions impair streptolysin O toxicity and group a Streptococcus virulence 160
New insights into the role of the glutamic acid of the E-box motif in group B Streptococcus pilus 2a assembly. 158
A structure-based approach to rationally design a chimeric protein for an effective vaccine against Group B Streptococcus infections. 153
FAT1: A potential target for monoclonal antibody therapy in colon cancer 153
Approach to discover T and B cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. 149
Structural Basis for Group B Streptococcus Pilus 1 Sortases C Regulation and Specificity 148
Cloning and nucleotide sequence of the isoamylase gene from a strain of Pseudomonas sp 145
Structural vaccinology starts to deliver 145
Recombinant outer membrane vesicles carrying Chlamydia muridarum HtrA induce antibodies that neutralize chlamydial infection in vitro 142
MF59- and Al(OH)3-adjuvanted Staphylococcus aureus (4C-Staph) vaccines induce sustained protective humoral and cellular immune responses, with a critical role for effector CD4 T cells at low antibody titers 140
A rapid and versatile site-directed method of mutagenesis for double-stranded plasmid DNA 138
ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer 137
The Protective Value of Maternal Group B Streptococcus Antibodies: Quantitative and Functional Analysis of Naturally Acquired Responses to Capsular Polysaccharides and Pilus Proteins in European Maternal Sera 137
Sequence and analysis of the genetic locus responsible for surfactin synthesis in Bacillus subtilis 136
Sequence type 1 group B Streptococcus, an emerging cause of invasive disease in adults, evolves by small genetic changes 136
Multiple Stepwise Gene Knockout Using CRISPR/Cas9 in Escherichia coli 136
Identification of new potential vaccine candidates against Chlamydia pneumoniae by multiple screenings 134
SpyAD, a moonlighting protein of group A Streptococcus contributing to bacterial division and host cell adhesion 131
Inferring reasons for the failure of Staphylococcus aureus vaccines in clinical trials. 130
Antibacterial vaccine design using genomics and proteomics 130
Antibody-mediated immunity induced by engineered Escherichia coli Outer Membrane Vesicles (OMVs) carrying heterologous antigens in their lumen 130
Engineering outer membrane vesicles 128
Rational antibacterial vaccine design through genomic technologies 128
A novel polyclonal antibody library for expression profiling of poorly characterized, membrane and secreted human proteins. 126
Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines 124
Three-dimensional human skin models to understand Staphylococcus aureus skin colonization and infection 123
Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP 122
Outer membrane vesicles from the gut microbiome contribute to tumor immunity by eliciting cross-reactive T cells 119
Functional activity of maternal and cord antibodies elicited by an investigational group B Streptococcus trivalent glycoconjugate vaccine in pregnant women. 117
Crystal structures of the components of the Staphylococcus aureus leukotoxin ED 116
Four-component Staphylococcus aureus vaccine 4C-staph enhances fcγ receptor expression in neutrophils and monocytes and mitigates S. aureus infection in neutropenic mice 115
The impact of genomics in vaccine discovery: achievements and lessons 114
Autoreactive Plasmablasts After B Cell Depletion With Rituximab and Relapses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis 109
Sortase A substrate specificity in GBS pilus 2a cell wall anchoring. 109
Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model 106
Staphylococcus aureus FhuD2 is involved in the early phase of staphylococcal dissemination and generates protective immunity in mice. 105
Immunogenicity and Pre-Clinical Efficacy of an OMV-Based SARS-CoV-2 Vaccine 104
Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen. 101
Anti-Tumor Efficacy of In Situ Vaccination Using Bacterial Outer Membrane Vesicles 100
A Bacillus subtilis large ORF coding for a polypeptide highly similar to polyketide synthases. 100
Structural vaccinology starts to deliver 95
Recombinant and truncated tetanus neurotoxin light chain: Cloning, expression, purification, and proteolytic activity 94
Multi High-Throughput Approach for Highly Selective Identification of Vaccine Candidates: the Group A Streptococcus Case. 93
Cumulative stabilizing effects of hydrophobic interactions on the surface of the neutral protease from Bacillus subtilis 91
Structure and protective efficacy of the Staphylococcus aureus autocleaving protease EpiP 91
Immobilized metal-ion affinity chromatography of human growth hormone 91
Gene expression profile in Neisseria meningitidis and Neisseria lactamica upon host-cell contact: from basic research to vaccine development 89
The complete genome sequence of the gram-positive bacterium Bacillus subtilis 88
Identification of vaccine candidates against serogroup B meningococcus genome sequencing. 87
TCTN2: A novel tumor marker with oncogenic properties 87
Structural and functional characterization of the Staphylococcus aureus virulence factor and vaccine candidate FhuD2 87
Phagocyte subsets and lymphocyte clonal deletion behind ineffective immune response to Staphylococcus aureus 84
Outer Membrane Vesicles From The Gut Microbiome Contribute to Tumor Immunity by Eliciting Cross-Reactive T Cells 83
Surface Interactome in Streptococcus pyogenes. 80
R-factor mediated suppression of the galacto-sensitive phenotype of E.coli K12 galE mutants. 79
Characterization of the locus encoding the [Ni-Fe] sulfhydrogenase from the archaeon Pyrococcus furiosus: evidence for a relationship to bacterial sulfite reductases. 75
Model building of a thermolysin-like protease by mutagenesis. 71
Mining the bacterial unknown proteome: Identification and characterization of a novel family of highly conserved protective antigens in Staphylococcus aureus 71
Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from Streptococcus pyogenes 71
Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis 71
tructure analysis and site-directed mutagenesis of defined key residues and motives for pilus-related sortase C1 in group B Streptococcus. 70
Purification of recombinant human growth hormone by isoelectric focusing in a multicompartment electrolyzer with Immobiline membranes. 65
Identification of novel iron-activated and -repressed fur-dependent genes by transcriptome analysis of Neisseria meningitidis group B 62
Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer 61
Efficient conversion of 5-substituted hydantoins to D-amino acids using recombinant E. coli strains 56
Grafting of a calcium binding loop of thermolysin to B. subtilis neutral protease. 49
Rheumatic immune-and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: A systematic review and meta-analysis 48
Investigation on antigen-specific T-cell responses induced by outer membrane vesicles from Escherichia coli Δ60 strain 23
Totale 11.930
Categoria #
all - tutte 48.423
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 48.423


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021196 0 0 0 0 0 0 0 0 0 0 0 196
2021/20221.081 57 149 18 99 28 42 34 219 59 96 118 162
2022/20231.018 150 154 23 134 89 156 10 80 108 8 57 49
2023/2024339 24 34 21 16 30 46 46 14 4 16 33 55
2024/20251.699 10 6 74 408 60 246 30 90 173 298 105 199
2025/20264.044 246 126 563 965 287 245 683 103 342 275 131 78
Totale 11.930